Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
135 hedge funds and large institutions have $1.28B invested in Mersana Therapeutics in 2020 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 55 increasing their positions, 37 reducing their positions, and 21 closing their positions.
231% more call options, than puts
Call options by funds: $9.83M | Put options by funds: $2.97M
49% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 37
24% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 21
4% more funds holding
Funds holding: 130 → 135 (+5)
0.1% more ownership
Funds ownership: 3.91% → 4.02% (+0.1%)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
17% less capital invested
Capital invested by funds: $1.53B → $1.28B (-$254M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
+$31.3M |
| 2 |
State Street
Boston,
Massachusetts
|
+$27.9M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$21.9M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$21.1M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$18.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$49.1M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$40.4M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$14.7M |
| 4 |
Millennium Management
New York
|
-$13.7M |
| 5 |
O
OrbiMed
New York
|
-$11.7M |
MRSN Hedge Fund Activity: Q3 2020 in Review
135 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q3 2020, worth a combined $1.28B — down 17% from $1.53B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new MRSN positions and 21 closed out — a net gain of 5 holders — while 55 added to existing stakes and 37 trimmed.
The largest buyer was Alkeon Capital Management, opening a new position worth an estimated $31.3M. The largest seller was Consonance Capital Management, cutting an estimated $49.1M.
- 135 institutional investors held Mersana Therapeutics (MRSN) as of Q3 2020, up from 130 in Q2 2020.
- Funds reported $1.28B of Mersana Therapeutics stock for Q3 2020, down 17% quarter-over-quarter.
- 26 funds opened new Mersana Therapeutics positions in Q3 2020 and 21 closed out, a net change of +5 holders.
- The largest Mersana Therapeutics buyer in Q3 2020 was Alkeon Capital Management, an estimated $31.3M added.
- The largest Mersana Therapeutics seller in Q3 2020 was Consonance Capital Management, an estimated $49.1M sold.
Based on aggregated 13F filings for Q3 2020.